STAGE III CUTANEOUS MELANOMA AJCC V7

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

This early-phase study tests whether giving patients with advanced melanoma their own genetically modified T-cells, followed by high-dose interleukin-2, is safe and feasible. The T-cells are altered in the lab to resist a protein that normally stops them from attacking tumors. Ab…

This study tests a combination of two drugs—T-VEC, a virus-based therapy that attacks tumors, and pembrolizumab, an immunotherapy that helps the immune system fight cancer—in people with advanced melanoma that has worsened after prior treatment. About 43 participants with stage I…

This study tests whether combining an immunotherapy drug (nivolumab) with two targeted drugs (either dabrafenib + trametinib or encorafenib + binimetinib) can shrink or control advanced melanoma that has spread to the brain or other organs. About 52 adults with a specific gene mu…

This early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking certain cell signals and a process called autophagy can slow…

This study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 245 participants received either the combination or ipilimumab alone. The main goal was to see if the …

This study tests whether taking a break from two targeted melanoma drugs (dabrafenib and trametinib) works as well as taking them every day. About 280 people with advanced BRAF-mutant melanoma that cannot be removed by surgery are participating. The goal is to see if intermittent…

This early-phase study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes cancer cells need to grow)—in people with advanced melanoma that cannot be removed by surgery. The main g…

This study tests whether adding a drug called sargramostim to two immunotherapy drugs (nivolumab and ipilimumab) helps people with advanced melanoma that cannot be removed by surgery. About 600 adults with stage III or IV melanoma will receive either the two-drug or three-drug co…